-
The second transfer on Euronext Oslo Børs this year
-
Market capitalisation of approximately NOK 317 million
Oslo – 22 October 2024 – Euronext Oslo Børs congratulates Lifecare (ticker: LIFE), a Norwegian medtech company listed since 2018, on its transfer from Euronext Growth Oslo to Euronext Oslo Børs. This is the second transfer this year between the Oslo markets.
Lifecare develops miniaturised and implantable long-term medical sensors for continuous monitoring of glucose and other biomarkers. The company has a particular focus on diabetes, helping the more than 500 million people living with the disease today. The company is headquartered in Bergen, Norway. Its research and development activities are performed in Mainz and Reutlingen in Germany and its chemistry lab is situated in Bristol, UK.
At opening, the share price was NOK 20 per share, based on the closing price on Euronext Growth Oslo on 21 October 2024. This corresponds to an estimated market capitalisation of
NOK 317 million.
Joacim Holter, CEO of Lifecare, said: “It is an important milestone for Lifecare to take the step to the regulated market Euronext Oslo Børs. On behalf of the entire organisation, I am very proud that Oslo Børs' listing committee has assessed and concluded that Lifecare meets the conditions for admission to the main market. We have a proven technology; we have focused on setting up production and we are now approaching our first product. Lifecare is now ready for the main market on Euronext Oslo Børs.”
Caption: Joacim Holter, CEO of Lifecare, rang the bell this morning to celebrate the transfer to Euronext Oslo Børs. The company was welcomed by Øivind Amundsen, CEO of Euronext Oslo Børs, and Eirik Høiby Ausland, Head of Listing at Euronext Oslo Børs. (Photo: Thomas Brun | NTB)
About Lifecare
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (CGM) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (NTR) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.
CONTACTS
| MEDIA – mediateam@euronext.com | |||
| Europe | Aurélie Cohen | +33 1 70 48 24 45 | mediateam@euronext.com |
| Andrea Monzani | +39 02 72 42 62 13 | ||
| Amsterdam | Marianne Aalders | +31 20 721 41 33 | amsterdampressoffice@euronext.com |
| Brussels | Marianne Aalders | +32 26 20 15 01 | brusselspressoffice@euronext.com |
| Dublin | Andrea Monzani | +39 02 72 42 62 13 |
dublinpressoffice@euronext.com
|
| Lisbon | Sandra Machado |
+351 91 777 68 97 |
portugalpressoffice@euronext.com
|
| Milan, Rome | Ester Russom | +39 02 72 42 67 56 | italypressoffice@euronext.com |
| Oslo | Cathrine Lorvik Segerlund | +47 41 69 59 10 | clsegerlund@euronext.com |
| Paris, Corporate | Flavio Bornancin-Tomasella | +33 1 70 48 24 45 | parispressoffice@euronext.com |
| Corporate Services | Coralie Patri | +33 7 88 34 27 44 | parispressoffice@euronext.com |
| ANALYSTS & INVESTORS – ir@euronext.com | |||
| Investor Relations | Aurélie Cohen | +33 1 70 48 24 17 | ir@euronext.com |
| Judith Stein | +33 6 15 23 91 97 | ir@euronext.com | |